Our business model is designed to bring solutions to patients while generating shareholder value, by translating our proprietary technology into commercial drug products in a rapid and cost-effective way.



Investment case

Silence is the only listed RNAi player in Europe and a pioneer in this technology. Through the efforts of our skilled scientists over the years we have established a robust platform that allows us to effectively trigger RNAi in specific cell types. Our inventions are protected by a broad intellectual property estate, which is a fundamental asset. Together with our progress, the fact that the field is generally maturing means that RNAi drugs are close to becoming a powerful genetic medicine modality at the disposal of doctors and patients.


Results, reports & presentations

Annual Report 2019

Showing: All Size

Half Year Results 2020

391KB Download

Full Year Results 2019

361KB Download

Half Year Results 2019

345KB Download

Full Year Results 2018

371KB Download

Half Year Results 2018

367KB Download

Annual Report 2019

1MB Download

Annual Report 2018

3MB Download

Annual Report 2017

2MB Download

Annual Report 2016

1MB Download

Annual Report 2015

978KB Download

Silence Therapeutics FY19 Results Announcement

175KB Download

Collaboration with AstraZeneca and R&D Update

176KB Download

Silence Therapeutics HY20 Results Announcement

Click here to register for the webcast

955KB Download

Canaccord 40th Annual Growth Conference

Click here to replay the webcast

215KB Download

BTIG Virtual Biotechnology Conference

Click here to replay the webcast

215KB Download

William Blair Biotech Focus Conference

Click here to replay the webcast

215KB Download

Silence Therapeutics Fireside Chat at the RBC Capital Markets Global Healthcare Virtual Conference

Click here to replay the webcast

163KB Download

Corporate governance 

Our Corporate Governance framework is based on using the leadership provided by our Board to drive the effective execution of our strategy, ensuring that risk is appropriately mitigated and managed.


We have three Board Committees (Remuneration, Audit and Risk, and Nominations), focused on providing the required oversight to maintaining the highest Corporate Governance standards. Through these committees and regular interactions with the executive team, our Board applies internal financial controls and approves the Company’s policy and strategy.